Laura C Torchen1,2. 1. Division of Endocrinology, Ann & Robert H Lurie Children's Hospital of Chicago, 225 E Chicago Ave, Box 54, Chicago, IL, 60611, USA. LTorchen@luriechildrens.org. 2. Feinberg School of Medicine, Northwestern University, Chicago, IL, 60611, USA. LTorchen@luriechildrens.org.
Abstract
PURPOSE OF REVIEW: Polycystic ovary syndrome (PCOS) is diagnosed by its characteristic reproductive features. However, PCOS is also associated with metabolic abnormalities, including insulin resistance and β-cell dysfunction. The severity of these abnormalities varies according to the reproductive phenotype, with the so-called NIH or classic phenotype conferring the greatest metabolic risk. The increased risk for type 2 diabetes (T2D) is well established among affected women with the NIH phenotype, but whether PCOS also confers an increased risk for cardiovascular events remains unknown. RECENT FINDINGS: Recent studies in daughters of affected women have found evidence for pancreatic β-cell dysfunction prior to menarche. Further, genetic analyses have provided evidence that metabolic abnormalities such as obesity and insulin resistance contribute to the pathogenesis of PCOS. PCOS increases the risk for T2D. However, the risk for cardiovascular disease has not been quantified, and prospective, longitudinal studies are still critically needed.
PURPOSE OF REVIEW: Polycystic ovary syndrome (PCOS) is diagnosed by its characteristic reproductive features. However, PCOS is also associated with metabolic abnormalities, including insulin resistance and β-cell dysfunction. The severity of these abnormalities varies according to the reproductive phenotype, with the so-called NIH or classic phenotype conferring the greatest metabolic risk. The increased risk for type 2 diabetes (T2D) is well established among affected women with the NIH phenotype, but whether PCOS also confers an increased risk for cardiovascular events remains unknown. RECENT FINDINGS: Recent studies in daughters of affected women have found evidence for pancreatic β-cell dysfunction prior to menarche. Further, genetic analyses have provided evidence that metabolic abnormalities such as obesity and insulin resistance contribute to the pathogenesis of PCOS. PCOS increases the risk for T2D. However, the risk for cardiovascular disease has not been quantified, and prospective, longitudinal studies are still critically needed.
Authors: N M O'Meara; J D Blackman; D A Ehrmann; R B Barnes; J B Jaspan; R L Rosenfield; K S Polonsky Journal: J Clin Endocrinol Metab Date: 1993-05 Impact factor: 5.958
Authors: Bart C J M Fauser; Basil C Tarlatzis; Robert W Rebar; Richard S Legro; Adam H Balen; Roger Lobo; Enrico Carmina; Jeffrey Chang; Bulent O Yildiz; Joop S E Laven; Jacky Boivin; Felice Petraglia; C N Wijeyeratne; Robert J Norman; Andrea Dunaif; Stephen Franks; Robert A Wild; Daniel Dumesic; Kurt Barnhart Journal: Fertil Steril Date: 2011-12-06 Impact factor: 7.329
Authors: Carlos Lorenzo; Lynne E Wagenknecht; Marian J Rewers; Andrew J Karter; Richard N Bergman; Anthony J G Hanley; Steven M Haffner Journal: Diabetes Care Date: 2010-09 Impact factor: 17.152
Authors: M Geoffrey Hayes; Margrit Urbanek; David A Ehrmann; Loren L Armstrong; Ji Young Lee; Ryan Sisk; Tugce Karaderi; Thomas M Barber; Mark I McCarthy; Stephen Franks; Cecilia M Lindgren; Corrine K Welt; Evanthia Diamanti-Kandarakis; Dimitrios Panidis; Mark O Goodarzi; Ricardo Azziz; Yi Zhang; Roland G James; Michael Olivier; Ahmed H Kissebah; Elisabet Stener-Victorin; Richard S Legro; Andrea Dunaif Journal: Nat Commun Date: 2015-08-18 Impact factor: 14.919
Authors: Lisa-Marie Sattler; Hanna A Schniewind; Waldemar B Minich; Christoph W Haudum; Petra Niklowitz; Julia Münzker; Gábor L Kovács; Thomas Reinehr; Barbara Obermayer-Pietsch; Lutz Schomburg Journal: PLoS One Date: 2021-04-02 Impact factor: 3.240